Protalix BioTherapeutics

PLX

Capitalización de mercado USD 211 M

Protalix BioTherapeutics, Inc. (PLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

CARMIEL, Israel, Sept. 8, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that Gilad Mamlok, Senior Vice President and Chief Financial Officer, is scheduled to participate in the following two upcoming investor conferences in New York City, New York: H.C.

Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript

Company to host conference call and webcast today at 8:00 a.m. EDT Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4 million from the second quarter of 2025, driven primarily by sales of Elfabrio® Total revenue climbed to $53.6 million, year to date, from $25.8 million for the same period in 2025, which includes the previously reported $25.0 million Chiesi milestone payment Year-to-date, the Company achieved profitability with a net income of $22.1 million The Company reiterates full-year 2026 guidance of $78.0 million to $83.0 million in total revenue PRX-115 Phase 2 study continues to advance as planned, with top-line results anticipated in the second half of 2027 Cash, cash equivalents, and short-term bank deposits were $40.7 million as of June 30, 2026, providing sufficient capital to fund ongoing operations including the Phase 2 RELEASE clinical trial of PRX-115 CARMIEL, Israel, Aug. 12, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the second quarter ended June 30, 2026, and provided a business and clinical update.

Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, Aug. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended June 30, 2026 and provide a business update on August 12, 2026.

Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript

Company to host conference call and webcast today at 8:00 a.m. EDT Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027 The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the Phase 2 RELEASE clinical trial of PRX-115 CARMIEL, Israel, May 13, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the first quarter ended March 31, 2026, and provided a business and clinical update.

Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, May 6, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended March 31, 2026 and provide a business update on May 13, 2026.

Protalix BioTherapeutics reported weaker FY25 results but issued robust FY26 revenue guidance of $78–83 million, well above consensus. PLX's growth thesis centers on Elfabrio's EU approval and once-every-4-weeks dosing, offering a clear competitive and patient adherence advantage. Chiesi's contribution is expected to exceed 50% revenue growth in 2026, improving margin mix and earnings predictability despite near-term volatility.

Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript